- Home
- PIM vs PLX Comparison
PIM vs PLX Comparison
Compare PIM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | PLX |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 182.9M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | PIM | PLX |
|---|---|---|
| Price | $3.10 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 46.6K | ★ 489.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.05 | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.80 | ★ $10.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.07 | $1.42 |
| 52 Week High | $3.50 | $3.19 |
Technical Indicators
Market Signals| Indicator | PIM | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 45.20 |
| Support Level | $3.07 | $2.25 |
| Resistance Level | $3.33 | $2.44 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 21.43 | 21.15 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.